Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN001 in metastatic castration-resistant prostate cancer
NCT02349139Phase 1Terminated
- Sponsor
- Asana BioSciences, LLC
- Start
- Jan 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASN001 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Asana BioSciences, LLC. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2015; status: terminated.
02
Drugs
ASN001
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02349139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349139.